SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$41.71 USD
+0.78 (1.91%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $41.73 +0.02 (0.05%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.71 USD
+0.78 (1.91%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $41.73 +0.02 (0.05%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum D VGM
Zacks News
SWTX's NDA for Rare Tumor Drug Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts and grants priority review to SpringWorks' NDA for mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas.
Here's Why You Should Invest in SpringWorks (SWTX) Stock Now
by Zacks Equity Research
Here, we are discussing some reasons why investing in SpringWorks (SWTX) stock now may turn out to be a prudent move.
How Much Upside is Left in SpringWorks Therapeutics (SWTX)? Wall Street Analysts Think 77.9%
by Zacks Equity Research
The mean of analysts' price targets for SpringWorks Therapeutics (SWTX) points to a 77.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SpringWorks (SWTX) Q2 Earnings Beat, Ogsiveo Drives Revenues
by Zacks Equity Research
SpringWorks (SWTX) reports better-than-expected second-quarter results. The newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
SpringWorks Therapeutics (SWTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
SpringWorks Therapeutics (SWTX) delivered earnings and revenue surprises of 51.79% and 73.09%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
SpringWorks (SWTX) Rises More Than 40% in a Year: Here's Why
by Zacks Equity Research
SpringWorks' (SWTX) Ogsiveo is the first drug approved by the FDA to treat desmoid tumors. The company's efforts to develop its pipeline candidate, mirdametinib, for treating NF1-PN also hold promise.
SpringWorks (SWTX) Completes NDA Submission for Mirdametinib
by Zacks Equity Research
SpringWorks (SWTX) completes the submission of a new drug application for its MEK inhibitor, mirdametinib, for treating patients with neurofibromatosis type 1- associated plexiform neurofibromas.
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
SpringWorks Therapeutics (SWTX) delivered earnings and revenue surprises of -0.85% and 76.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
by Zacks Equity Research
Immunome (IMNM) inks an asset purchase agreement with Ayala Pharmaceuticals to acquire the latter's investigational candidate, AL102, being developed for treating desmoid tumors. Stock rises.
SpringWorks (SWTX) Surges More Than 80% in 3 Months: Here's Why
by Zacks Equity Research
SpringWorks (SWTX) receives a big boost with the FDA's approval for Ogsiveo (nirogacestat) to treat adult patients with progressing desmoid tumors.
SpringWorks (SWTX) Rises on FDA Nod for Desmoid Tumor Drug
by Zacks Equity Research
The FDA approves SpringWorks' (SWTX) Ogsiveo (nirogacestat) for the treatment of adult patients with desmoid tumors. Shares rise.
SpringWorks (SWTX) Falls Despite Positive Mirdametinib Study Data
by Zacks Equity Research
SpringWorks (SWTX) posts encouraging data from phase IIb study on its MEK inhibitor, mirdametinib for treating neurofibromatosis type 1-associated plexiform neurofibromas. Stock falls.
Wall Street Analysts Think SpringWorks Therapeutics (SWTX) Could Surge 212%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for SpringWorks Therapeutics (SWTX) points to a 211.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why You Should Consider Investing in JAZZ Stock Now
by Zacks Equity Research
JAZZ's new drugs like Xywav, Rylaze and Zepzelca, along with the recently-acquired drugs, are expected to generate 65% of product revenues in 2022.
SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma
by Zacks Equity Research
Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.
SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal
by Zacks Equity Research
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.
Allogene (ALLO) Focuses on Pipeline Amid Lack of Marketed Drugs
by Zacks Equity Research
With no product revenues due to the lack of marketed drugs, Allogene (ALLO) focuses on developing its pipeline candidates that mainly consist of allogenic CAR T therapies.
SpringWorks (SWTX) & AbbVie Unite for Multiple Myeloma Drug
by Zacks Equity Research
SpringWorks Therapeutics (SWTX) collaborates with AbbVie (ABBV) to evaluate the combination of nirogacestat with AbbVie's ABBV-383 for relapsed or refractory multiple myeloma.
Allogene (ALLO) Falls on FDA Clinical Hold on CAR-T Studies
by Zacks Equity Research
The FDA places Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates on hold, following chromosomal abnormality observed in an early-stage study patient receiving ALLO-501A.
New Strong Sell Stocks for August 13th
by Zacks Equity Research
LASR, TWLO, SWTX, FSLY, and UUUU have been added to the Zacks Rank #5 (Strong Sell) List on August 13, 2021
Allogene (ALLO) Q2 Earnings Top, Sales Lag, Pipeline Advances
by Zacks Equity Research
Allogene (ALLO) beats earnings estimates but misses the same for revenues in the second quarter.
New Strong Sell Stocks for June 10th
by Zacks Equity Research
AREC, RNLSY, and SWTX have been added to the Zacks Rank #5 (Strong Sell) List on June 10, 2021.
Allogene (ALLO) Q1 Earnings & Sales Beat, Pipeline Advances
by Zacks Equity Research
Allogene (ALLO) beats earnings and revenue estimates in the first quarter. Stock gains 1.7%.
Allogene (ALLO) CAR T Therapy for Myeloma Gets FDA RMAT Tag
by Zacks Equity Research
FDA grants RMAT designation to Allogene's (ALLO) CAR T cell product candidate for multiple myeloma, ALLO-715. The designation will help accelerate development and review of the candidate.
SpringWorks (SWTX) Begins Dosing in Multiple Myeloma Study
by Zacks Equity Research
SpringWorks (SWTX) doses the first patient in a phase Ib study evaluating nirogacestat in combination with teclistamab for the treatment of relapsed or refractory multiple myeloma.